Barbara Klencke Acquires 5,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock

TScan Therapeutics, Inc. (NASDAQ:TCRX) Director Barbara Klencke purchased 5,000 shares of the stock in a transaction dated Monday, September 23rd. The stock was purchased at an average price of $5.29 per share, with a total value of $26,450.00. Following the completion of the acquisition, the director now directly owns 45,000 shares in the company, valued at approximately $238,050. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Barbara Klencke also recently made the following trade(s):

• On Monday, August 26th, Barbara Klencke purchased 5,000 shares of TScan Therapeutics stock. The stock was purchased at an average price of $5.53 per share, with a total value of $27,650.00.
• On Friday, August 23rd, Barbara Klencke acquired 5,000 shares of TScan Therapeutics stock. The shares were bought at an average price of $5.69 per share, with a total value of $28,450.00.

TScan Therapeutics Trading Down 1.6 %

Shares of TScan Therapeutics stock opened at $5.02 on Thursday. The company has a quick ratio of 7.77, a current ratio of 7.77 and a debt-to-equity ratio of 0.08. The firm has a market cap of $265.37 million, a price-to-earnings ratio of -3.92 and a beta of 0.79. The business has a fifty day simple moving average of $6.00 and a 200-day simple moving average of $7.02. TScan Therapeutics, Inc. has a fifty-two week low of $2.43 and a fifty-two week high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.02. The business had revenue of $0.54 million during the quarter, compared to analyst estimates of $1.55 million. TScan Therapeutics had a negative return on equity of 59.83% and a negative net margin of 855.84%. On average, equities analysts forecast that TScan Therapeutics, Inc. will post -1.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on TCRX shares. Wedbush restated an “outperform” rating and set a $10.00 price objective on shares of TScan Therapeutics in a research note on Monday, August 12th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of TScan Therapeutics in a research report on Monday, August 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, TScan Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $12.00.

Institutional Trading of TScan Therapeutics

Institutional investors have recently modified their holdings of the company. Pale Fire Capital SE raised its position in shares of TScan Therapeutics by 30.2% during the fourth quarter. Pale Fire Capital SE now owns 21,573 shares of the company’s stock worth $126,000 after purchasing an additional 4,998 shares during the period. Cannon Global Investment Management LLC acquired a new stake in shares of TScan Therapeutics during the first quarter worth $139,000. Tocqueville Asset Management L.P. acquired a new stake in shares of TScan Therapeutics during the first quarter worth $1,685,000. Vanguard Group Inc. raised its position in shares of TScan Therapeutics by 1.1% during the first quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock worth $14,357,000 after purchasing an additional 20,000 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of TScan Therapeutics during the second quarter worth $682,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.